EGFR and metastatic colorectal cancer: Several clinical trials have demonstrated that patients with unresectable metastatic colorectal cancer (mCRC) benefit from targeted therapy, particularly the anti-epidermal growth factor receptor (EGFR) antibody, cetuximab (CTX), which has been reported to significantly improve progression-free survival (PFS) and overall survival (OS) within the RAS/BRAF wild-type (wt) mCRC population [3].